@article{03827d82e1244624bb2831c130a569ad,
title = "Biocatalysis for the synthesis of pharmaceuticals and pharmaceutical intermediates",
abstract = "Biocatalysis has been increasingly used for pharmaceutical synthesis in an effort to make manufacturing processes greener and more sustainable. Biocatalysts that possess excellent activity, specificity, thermostability and solvent-tolerance are highly sought after to meet the requirements of practical applications. Generating biocatalysts with these specific properties can be achieved by either discovery of novel biocatalysts or protein engineering. Meanwhile, chemoenzymatic routes have also been designed and developed for pharmaceutical synthesis on an industrial scale. This review discusses the recent discoveries, engineering, and applications of biocatalysts for the synthesis of pharmaceuticals and pharmaceutical intermediates. Key classes of biocatalysts include reductases, oxidases, hydrolases, lyases, isomerases, and transaminases.",
keywords = "Biocatalysis, Hydrolases, Isomerases, Lyases, Oxidases, Pharmaceutical intermediates, Pharmaceuticals, Reductases, Transaminases",
author = "Huihua Sun and Hongfang Zhang and Ang, {Ee Lui} and Huimin Zhao",
note = "Funding Information: We thank the National Institutes of Health (GM077596) (H.Z.), the GlaxoSmithKline—Singapore Economic Development Board partnership for green and sustainable manufacturing (E.L.A.), the Energy Efficiency & Resources Core Technology Program of the Korea Institute of Energy Technology Evaluation and Planning (KETEP), granted financial resource from the Ministry of Trade, Industry & Energy, Republic of Korea (20153030091450) (H.Z.), and the Agency for Science, Research and Technology of Singapore Visiting Investigator Program (H.Z.) for financial support in our development and application of biocatalysis technologies. We thank all Zhao group members for giving critical comments during the preparation of this review. We also thank Dr. Wu Shuke from Department of Chemical & Biomolecular Engineering, National University of Singapore, for giving helpful suggestions during the revision of this review. In addition, we state that there is no conflict of interest. Funding Information: We thank the National Institutes of Health ( GM077596 ) (H.Z.), the GlaxoSmithKline—Singapore Economic Development Board partnership for green and sustainable manufacturing (E.L.A.), the Energy Efficiency & Resources Core Technology Program of the Korea Institute of Energy Technology Evaluation and Planning (KETEP), granted financial resource from the Ministry of Trade, Industry & Energy, Republic of Korea ( 20153030091450 ) (H.Z.), and the Agency for Science, Research and Technology of Singapore Visiting Investigator Program (H.Z.) for financial support in our development and application of biocatalysis technologies. We thank all Zhao group members for giving critical comments during the preparation of this review. We also thank Dr. Wu Shuke from Department of Chemical & Biomolecular Engineering, National University of Singapore, for giving helpful suggestions during the revision of this review. In addition, we state that there is no conflict of interest. Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",
year = "2018",
month = apr,
day = "1",
doi = "10.1016/j.bmc.2017.06.043",
language = "English (US)",
volume = "26",
pages = "1275--1284",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "7",
}